116 related articles for article (PubMed ID: 1691567)
21. Immunogenicity of a new type of yeast-derived hepatitis B vaccine consisting of M (pre-S2 + S) protein particles.
Hazama M; Takaoki M; Ohfune K; Hinuma S; Fujisawa Y
Vaccine; 1989 Dec; 7(6):567-73. PubMed ID: 2532813
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
Nemecková S; Sroller V; Kunke D; Krystofová J; Kutinová L
Acta Virol; 1996; 40(5-6):273-9. PubMed ID: 9171455
[TBL] [Abstract][Full Text] [Related]
23. Need for immunoprophylaxis in infants born to HBsAg-positive carrier mothers who are HBeAg negative.
Tong MJ; Sinatra FR; Thomas DW; Nair PV; Merritt RJ; Wang DW
J Pediatr; 1984 Dec; 105(6):945-7. PubMed ID: 6239022
[No Abstract] [Full Text] [Related]
24. Recombinant hepatitis B triple antigen vaccine: Hepacare.
Zuckerman JN; Zuckerman AJ
Expert Rev Vaccines; 2002 Aug; 1(2):141-4. PubMed ID: 12901552
[TBL] [Abstract][Full Text] [Related]
25. A study of the antigenicity and immunogenicity of a new hepatitis B vaccine using a panel of monoclonal antibodies.
Waters JA; Bailey C; Love C; Thomas HC
J Med Virol; 1998 Jan; 54(1):1-6. PubMed ID: 9443102
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
Raz R; Koren R; Bass D
Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
[TBL] [Abstract][Full Text] [Related]
27. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers.
Poovorawan Y; Sanpavat S; Pongpunlert W; Chumdermpadetsuk S; Sentrakul P; Safary A
JAMA; 1989 Jun; 261(22):3278-81. PubMed ID: 2523981
[TBL] [Abstract][Full Text] [Related]
28. Selective expression of immunogenic, virus-like particle-derived antibody-binding epitopes.
El Kholy S; Riedl P; Kwissa M; Reimann J; Schirmbeck R
Intervirology; 2002; 45(4-6):251-9. PubMed ID: 12566707
[TBL] [Abstract][Full Text] [Related]
29. T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice.
Jones CD; Page M; Bacon A; Cahill E; Bentley M; Chatfield SN
Vaccine; 1999 Jun; 17(20-21):2528-37. PubMed ID: 10418899
[TBL] [Abstract][Full Text] [Related]
30. Protective immunisation against hepatitis B with an internal antigen of the virus.
Murray K; Bruce SA; Wingfield P; van Eerd P; de Reus A; Schellekens H
J Med Virol; 1987 Oct; 23(2):101-7. PubMed ID: 2445909
[TBL] [Abstract][Full Text] [Related]
31. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.
Shouval D; Roggendorf H; Roggendorf M
Med Microbiol Immunol; 2015 Feb; 204(1):57-68. PubMed ID: 25557605
[TBL] [Abstract][Full Text] [Related]
32. [Hepatitis B core antigen as a carrier of functionally active epitopes: exposure of pre-S sites on capsids].
Borisova GP; Berzin' IG; Tsibinogin VV; Loseva VIa; Pushko PM; Ose VP; Dreĭlina DE; Pumpen PP; Gren EIa
Dokl Akad Nauk SSSR; 1990; 312(3):751-4. PubMed ID: 1699713
[No Abstract] [Full Text] [Related]
33. Interactions of hepatitis B virus with hepatocytes: mechanism and clinical relevance.
Theilmann L; Goeser T
Hepatogastroenterology; 1991 Feb; 38(1):10-3. PubMed ID: 1709133
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down's syndrome.
Van Damme P; Vranckx R; Meheus A
Vaccine; 1990 Mar; 8 Suppl():S53-5; discussion S60-2. PubMed ID: 2139285
[TBL] [Abstract][Full Text] [Related]
35. New vaccination strategies for low- and non-responders to hepatitis B vaccine.
Rendi-Wagner P; Wiedermann G; Stemberger H; Kollaritsch H
Wien Klin Wochenschr; 2002 Mar; 114(5-6):175-80. PubMed ID: 12238305
[TBL] [Abstract][Full Text] [Related]
36. Novel hepatitis B vaccines.
Zuckerman AJ
J Infect; 1986 Jul; 13 Suppl A():61-71. PubMed ID: 2427591
[TBL] [Abstract][Full Text] [Related]
37. Comparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2 + S antigens.
Miskovsky E; Gershman K; Clements ML; Cupps T; Calandra G; Hesley T; Ioli V; Ellis R; Kniskern P; Miller W
Vaccine; 1991 May; 9(5):346-50. PubMed ID: 1872019
[TBL] [Abstract][Full Text] [Related]
38. A novel, recombinant triple antigen hepatitis B vaccine (Hepacare).
Page M; Jones CD; Bailey C
Intervirology; 2001; 44(2-3):88-97. PubMed ID: 11509870
[TBL] [Abstract][Full Text] [Related]
39. Human T-helper cell responses to a synthetic peptide derived from the hepatitis B surface antigen.
Mishra A; Rao KV; Durgapal H; Manivel V; Panda SK
Immunology; 1993 Jul; 79(3):362-7. PubMed ID: 7691722
[TBL] [Abstract][Full Text] [Related]
40. Immunological cross-reactivities of woodchuck and hepatitis B viral antigens.
Millman I; Halbherr T; Simmons H
Infect Immun; 1982 Feb; 35(2):752-7. PubMed ID: 6173330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
